Immunopharmacologic Monitoring of Therapeutic Serum Antibodies
Customize your policy alerts
Sign up for all blue cross blue shield - tennessee policy alerts
Know when blue cross blue shield - tennessee releases new policies or updates existing guidance.
Monitor payer policy activity
Defines coverage criteria for measurement of serum drug concentrations and anti-drug antibodies to guide management of biologic therapies, focusing primarily on inflammatory bowel disease (IBD) patients and specifying noncoverage for most other indications.
No material clinical or coverage changes in this revision.
Coverage Criteria for Therapeutic Drug Monitoring
IBD — Anti-TNF testing (covered)
Covered when ANY of the following (for individuals with IBD):
From policy Indications and/or Limitations of Coverage.
IBD — Vedolizumab/ustekinumab testing (covered)
Covered when ANY of the following (for individuals with IBD receiving vedolizumab or ustekinumab):
From policy Indications and/or Limitations of Coverage.
Not covered — Non-IBD and other situations
From Reimbursement Policy noncoverage list.
Appropriate scenarios for TDM (anti‑TNFs)
Consensus statements and guideline‑based scenarios where ordering drug/antibody concentration testing is appropriate:
Consensus agreement reported across guideline statements (Papamichael et al.).
Vedolizumab and Ustekinumab
Agents with limited consensus for proactive monitoring:
Evidence weaker for proactive TDM with these agents (Papamichael et al.).
Certolizumab concentration target
Covered when ALL of the following are met:
From guideline statement in policy.
Golimumab concentration targets
Covered when ALL of the following are met:
From guideline statement in policy.
From guideline statement in policy.
Vedolizumab and Ustekinumab — limited evidence
Guidance / informational:
From guideline statement in policy.
Testing for drug and/or antibody concentrations for anti‑TNF therapies in indications other than inflammatory bowel disease (for example, spondyloarthritis, rheumatoid arthritis, psoriatic arthritis, and psoriasis) does not meet coverage criteria and may be denied. This exclusion also extends to measurement of serum drug levels or anti‑drug antibodies in clinical situations not explicitly listed as covered in this policy, including for the following agents: adalimumab, certolizumab, etanercept, golimumab, infliximab (and infliximab biosimilars), rituximab, ustekinumab, and vedolizumab.
The National Institute for Health and Care Excellence (NICE) concluded that while ELISA kits for therapeutic monitoring of TNF‑alpha inhibitors in Crohn's disease show promise, there is insufficient evidence to recommend their routine adoption. NICE recommends that ELISA testing be used only as part of research or data‑collection activities and similarly notes insufficient evidence to support routine ELISA use for rheumatoid arthritis.
For vedolizumab and ustekinumab the evidence is currently insufficient to define specific quantitative induction or maintenance concentration targets. Available guidance recommends only confirming the presence of drug (i.e., a detectable drug concentration) rather than applying firm numeric trough targets for clinical decisions.
Measurement of serum drug levels and/or anti‑drug antibodies for the listed biologic agents does not meet coverage criteria when requested for situations that are not specifically covered by this policy. Requests outside the covered IBD scenarios should be considered not medically necessary and may be denied.
Routine adoption of ELISA‑based therapeutic drug monitoring for TNF inhibitors is not currently supported by NICE because of limited evidence for clinical benefit. NICE specifies that ELISA testing should be limited to research and data collection until further evidence clarifies clinical effectiveness and appropriate use.
Procedure Codes and Drug Concentration Targets
| not specified | Laboratory assay portfolios (e.g., OptimAbs, Prometheus Anser, LabCorp DoseASSURE) for multiple biologics — company product listings rather than discrete CPT/HCPCS codes |
Provider Actions, Documentation, and Billing Guidance
TDM May Trigger Utilization Review
Therapeutic drug monitoring (TDM) for biologic therapies (proactive or reactive) may trigger utilization review when results are used to guide management decisions (for example, at end of induction, during maintenance, or to evaluate primary nonresponse or secondary loss of response). Providers should document clinical rationale for testing and how measured drug and/or antibody levels will inform specific treatment actions (dose intensification, interval adjustment, switching agents, or class change).
- TDM may prompt utilization review when used to direct clinical management (end of induction, maintenance checks, primary nonresponse, confirmed secondary loss of response).
- Document why testing is being ordered and how results will change management (e.g., dose escalation vs switching biologics).
Documentation for Covered IBD Testing
Documentation must support that the individual has inflammatory bowel disease (IBD) and meets one of the covered scenarios (e.g., end of induction for anti‑TNFs, at least once during maintenance, end of induction in primary non‑responders, or confirmed secondary loss of response). For vedolizumab and ustekinumab, documentation should support testing at end of induction in non‑responders or for confirmed secondary loss of response.
- Attach clinical notes confirming IBD diagnosis and the specific covered indication for testing (post‑induction, maintenance, primary nonresponse, or secondary loss of response).
- Indicate prior therapies, current dosing schedule, and objective evidence of response or loss of response (symptoms, endoscopy, biomarkers).
Documentation of Clinical Rationale and Measured Levels
Providers should include the clinical rationale and the measured drug and antibody levels in the record, and describe the intended management decision based on those values (for example: subtherapeutic trough → dose intensification; high‑titer antibodies → consider switching biologic or changing drug class). Quality‑improvement and outcomes data support post‑induction and reactive TDM to guide dose optimization in many IBD patients; include references to measured thresholds when used to support the plan.
- Record the exact assay result (drug concentration in µg/mL, antibody presence/titer) and the date/time relative to dosing (trough vs non‑trough).
- State the action to be taken if results meet predefined thresholds (e.g., specific trough cutoffs, presence of high‑titer antibodies).
- If following an algorithm, note which algorithm or guideline informed the decision (include citation or local protocol).
Testing to Inform Biologic Switching
Testing results are commonly used to inform whether to intensify dose, shorten dosing interval, switch to an alternative biologic, or change therapeutic class. Patients with high‑titer antidrug antibodies are more likely to be switched to another biologic, while low drug levels without antibodies may prompt dose optimization. Specify in documentation how results will inform switching or dose adjustments.
- Document whether the plan is dose intensification, interval shortening, switching within class, or switching to a different mechanism of action.
- Include evidence (antibody titer, drug trough) that supports the chosen strategy and anticipated monitoring after the change.
Laboratory Test Validation
Laboratory‑developed tests (LDTs) used for therapeutic drug monitoring must be performed and validated in‑house under CLIA as high‑complexity tests. Note whether the assay is an LDT or an FDA‑cleared/approved kit, and ensure the lab validation status is documented.
- Indicate the performing laboratory and whether the assay is an LDT; include CLIA certification information when available.
- Confirm that the lab follows appropriate validation procedures for sensitivity, specificity, and reproducibility.
Procedure Coding Reference and Coding Note
Procedure and billing codes are provided as general reference only. Use the performing laboratory’s billing guidance and payer requirements to determine the correct codes. Providers should include the clinical indication and test specifics on claims to support medical necessity.
- Commonly referenced CPT/HCPCS codes include 80145 (adalimumab), 80230 (infliximab), 80280 (vedolizumab), 80299 (quantitation of therapeutic drug, NOS), 82397 (chemiluminescent assay), and 84999 (unlisted chemistry procedure).
- Procedure codes in this policy are not exhaustive — confirm coding with the lab and payer prior to billing.
Government Policy Precedence
If there is a conflict between this policy and any applicable government coverage (e.g., Medicare LCDs/NCDs or state Medicaid policies), the government policy will govern the coverage determination. Providers should check and cite the relevant LCD/NCD or state Medicaid policy when submitting requests for members covered under those programs.
- Verify and cite applicable Local Coverage Determinations (LCDs), National Coverage Determinations (NCDs), or state Medicaid guidance when ordering or billing.
- Follow government policy precedence for Medicare and Medicaid members; include the referenced policy number/date in the documentation when relevant.
Background and Rationale
TNF inhibitors are widely used to treat inflammatory conditions but can elicit anti‑drug antibodies that reduce drug exposure and efficacy and may cause adverse effects. Therapeutic drug monitoring (measuring trough drug concentrations and anti‑drug antibodies) has the strongest evidence and guideline support in inflammatory bowel disease; for most other indications the literature is insufficient to support routine testing.
Definitions and Terminology
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.